Literature DB >> 21480671

Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.

Joeri Kuil1, Tessa Buckle, Hushan Yuan, Nynke S van den Berg, Shinya Oishi, Nobutaka Fujii, Lee Josephson, Fijs W B van Leeuwen.   

Abstract

The antagonistic Ac-TZ14011 peptide, which binds to the chemokine receptor 4, has been labeled with a multifunctional single attachment point reagent that contains a DTPA chelate and a fluorescent dye with Cy5.5 spectral properties. Flow cytometry and confocal microscopy showed that the bimodal labeled peptide gave a specific receptor binding that is similar to monofunctionalized peptide derivatives. Therefore, the newly developed bimodal peptide derivative can be used in multimodal imaging applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21480671      PMCID: PMC3711080          DOI: 10.1021/bc2000947

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  23 in total

Review 1.  Molecular imaging with bioconjugates in mouse models of cancer.

Authors:  Stephen Mather
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

2.  Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening.

Authors:  Wataru Nomura; Yasuaki Tanabe; Hiroshi Tsutsumi; Tomohiro Tanaka; Kenji Ohba; Naoki Yamamoto; Hirokazu Tamamura
Journal:  Bioconjug Chem       Date:  2008-08-16       Impact factor: 4.774

3.  The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to the chemokine receptor CXCR4 via a novel WW domain-mediated interaction.

Authors:  Deepali Bhandari; Seth L Robia; Adriano Marchese
Journal:  Mol Biol Cell       Date:  2008-12-30       Impact factor: 4.138

Review 4.  'Two is better than one'--probes for dual-modality molecular imaging.

Authors:  Lucy E Jennings; Nicholas J Long
Journal:  Chem Commun (Camb)       Date:  2009-05-05       Impact factor: 6.222

5.  The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Authors:  Ombretta Salvucci; Amélie Bouchard; Andrea Baccarelli; Jean Deschênes; Guido Sauter; Ronald Simon; Rosella Bianchi; Mark Basik
Journal:  Breast Cancer Res Treat       Date:  2005-12-13       Impact factor: 4.872

6.  The molecular structure of indium-DTPA.

Authors:  H R Maecke; A Riesen; W Ritter
Journal:  J Nucl Med       Date:  1989-07       Impact factor: 10.057

7.  Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.

Authors:  Shinya Oishi; Ryo Masuda; Barry Evans; Satoshi Ueda; Yukiko Goto; Hiroaki Ohno; Akira Hirasawa; Gozoh Tsujimoto; Zixuan Wang; Stephen C Peiper; Takeshi Naito; Eiichi Kodama; Masao Matsuoka; Nobutaka Fujii
Journal:  Chembiochem       Date:  2008-05-05       Impact factor: 3.164

8.  Simplified syntheses of complex multifunctional nanomaterials.

Authors:  Elisabeth Garanger; Elena Aikawa; Fred Reynolds; Ralph Weissleder; Lee Josephson
Journal:  Chem Commun (Camb)       Date:  2008-08-13       Impact factor: 6.222

Review 9.  Multimodality molecular imaging with combined optical and SPECT/PET modalities.

Authors:  Joseph Culver; Walter Akers; Samuel Achilefu
Journal:  J Nucl Med       Date:  2008-01-16       Impact factor: 10.057

10.  Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives.

Authors:  Hirokazu Tamamura; Kenichi Hiramatsu; a Shuichi Kusano; Shigemi Terakubo; Naoki Yamamoto; John O Trent; Zixuan Wang; Stephen C Peiper; Hideki Nakashima; Akira Otaka; Nobutaka Fujii
Journal:  Org Biomol Chem       Date:  2003-11-07       Impact factor: 3.876

View more
  24 in total

Review 1.  CXCR4-based imaging agents.

Authors:  Lauren E Woodard; Sridhar Nimmagadda
Journal:  J Nucl Med       Date:  2011-11       Impact factor: 10.057

Review 2.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 3.  Nuclear and Optical Bimodal Imaging Probes Using Sequential Assembly: A Perspective.

Authors:  Shin Hye Ahn; Eszter Boros
Journal:  Cancer Biother Radiopharm       Date:  2018-07-13       Impact factor: 3.099

4.  Deep-red fluorescent imaging probe for bacteria.

Authors:  Alexander G White; Brian D Gray; Koon Yan Pak; Bradley D Smith
Journal:  Bioorg Med Chem Lett       Date:  2012-03-03       Impact factor: 2.823

5.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.

Authors:  Yan Wang; Ying Xie; David Oupický
Journal:  Curr Pharmacol Rep       Date:  2016-01-04

6.  Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.

Authors:  Anton Bunschoten; Tessa Buckle; Nils L Visser; Joeri Kuil; Hushan Yuan; Lee Josephson; Alexander L Vahrmeijer; Fijs W B van Leeuwen
Journal:  Chembiochem       Date:  2012-04-13       Impact factor: 3.164

7.  Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents.

Authors:  Ole Tietz; Nazila Kamaly; Graham Smith; Elham Shamsaei; Kishore K Bhakoo; Nicholas J Long; Eric O Aboagye
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-07-10

8.  Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.

Authors:  Joeri Kuil; Tessa Buckle; Joppe Oldenburg; Hushan Yuan; Alexander D Borowsky; Lee Josephson; Fijs W B van Leeuwen
Journal:  Mol Pharm       Date:  2011-11-15       Impact factor: 4.939

9.  Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.

Authors:  Wojciech G Lesniak; Emilia Sikorska; Hassan Shallal; Babak Behnam Azad; Ala Lisok; Mrudula Pullambhatla; Martin G Pomper; Sridhar Nimmagadda
Journal:  Mol Pharm       Date:  2015-02-03       Impact factor: 4.939

Review 10.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.